UA138787U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes a clinical examination, radiography. Additionally, the polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), endothelin, glycosaminoglycan (GAG), homocysteine genes is determined in the patient's serum. With a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, GAG> 28 μmol / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, according to a useful model, polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (eMO5 17860), endothelin content, are additionally determined in the patient's blood serum. of glycosaminoglycans (GAG), homocysteine and with homozygous carriers of 677-TT, 786-SS and endothelin levels of 210 ng/ml,

GAG 228 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

The method is used as follows:

During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEVK Sb677T, eMmO5 T786C genes is determined, and the content of endothelin, GAG, and homocysteine is determined by the immunoenzymatic method. With homozygous carriers of 677-TT, 786-SS, levels of endothelin 210 ng/ml, GAG »28 μmol/l, homocysteine 220 μmol/l ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient G., 66 years old, was hospitalized in the clinic due to pain syndrome of the left hip joint. X-rays were examined and carried out. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and emo5 17860 genes was determined in blood serum. The content of endothelin, GAG, and homocysteine was determined by immunoenzymatic method. A homozygous carrier of 677-111 and 786-SS was established, endothelin levels - 25 ng/ml, GAG - 48 μmol/l, homocysteine - 33 μmol/l.

The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed phenomena

From osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the genes methylenetetrahydrofolate reductase (MINEV Сб677Т), nitric oxide synthase (емМмо5 T786С), the content of endothelin, glycosaminoglycans (GAG), homocysteine and with homozygous carriers of 677-TT, 786-SS and levels of endothelin 210 ng/ml, GAG »28 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.